#United States #New York #Pomerantz LLP #Abeona Therapeutics #ABEO

Pomerantz Law Firm Turns Its Attention to Abeona Therapeutics

Pomerantz LLP, a renowned law firm with a history of championing investors' rights, is currently scrutinizing Abeona Therapeutics Inc. (NASDAQ: ABEO) over allegations of securities fraud. The investigation arises from claims and circumstances surrounding the company's operations that may have misled investors. The firm has invited investors who may have suffered losses to come forward and share their experiences.

The legal inquiry comes on the heels of a press release from Abeona dated August 13, 2026, where the company provided details about its second-quarter financial results and the commercial execution of its product ZEVASKYN (prademagene zamikeracel). During this announcement, Abeona revealed that although five patients were administered the therapy, only four were officially recognized for revenue purposes due to a production issue involving one batch.

This revelation triggered a sharp decrease in the company's stock price, falling by $1.12 or approximately 14.95%, which closed at $6.35 following the announcement. Such drastic price fluctuations raise red flags about the company's operational transparency and financial practices.

Historically, Pomerantz has been at the forefront of protecting investors against corporate misconduct. Founded by Abraham L. Pomerantz, a pioneer in class-action lawsuits, the firm has built a reputation for tackling serious securities violations, striving for justice for those affected by fraudulent business practices. They have a proven record of securing substantial settlements for investors harmed by misleading or unethical corporate behavior.

Pomerantz’s investigation aims to determine whether Abeona and its executives have engaged in misconduct that violates securities laws. The firm encourages affected investors to reach out, highlighting their commitment to pursuing justice in this complex matter.

With offices strategically located in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz boasts a global presence and expertise in class-action litigation. Their ongoing investigation into Abeona reflects their dedication to uncovering the truth and holding those in power accountable.

As this situation develops, it serves as a reminder of the importance of transparency and integrity in the biotechnology sector. Investors and stakeholders continue to monitor how Abeona will address these allegations and what actions will be taken to rectify any uncovered violations.

Those with insights into the situation or who believe they have been impacted by Abeona Therapeutics are urged to contact Danielle Peyton at Pomerantz LLC for guidance and potential participation in the class action. In the world of investment, situations like this emphasize the necessity for due diligence and the valuable role of legal advocates in safeguarding investors' interests.

For more information about the investigation or to see if you may qualify for compensation, investors can reach out directly to Pomerantz LLP by contacting Danielle Peyton at the provided email or phone number.

Stay tuned for further updates as Pomerantz continues its investigation into Abeona Therapeutics and seeks to deliver justice for harmed investors.